AbbVie reports that the trial of 15 mg of orally-administered, once-daily upadacitinib met its primary endpoints, with 71% of patients achieving 20% improvement based on American College of Rheumatology criteria (ACR20), and 29% achieving clinical remission.
This week, drug manufacturer AbbVie announced positive top-line results from its phase 3 SELECT-COMPARE clinical trial that investigated upadacitinib, a Janus kinase (JAK) inhibitor, versus placebo and versus adalimumab, an anti—tumor necrosis factor inhibitor, in patients with rheumatoid arthritis (RA).
AbbVie reports that the trial of 15 mg of orally-administered, once-daily upadacitinib met its primary endpoints, with 71% of patients achieving 20% improvement based on American College of Rheumatology criteria (ACR20), and 29% achieving clinical remission.
Furthermore, upadacitinib was superior to adalimumab on ranked secondary endpoints: at week 12, 45% of patients receiving upadacitinib achieved ACR50 (versus 29% of patients receiving adalimumab), and upadacitinib also demonstrated greater reductions of pain (measured by the Patient's Assessment of Pain) and greater improvements in physical function (measured by Health Assessment Questionnaire-Disability Index) at week 12. Upadacitinib also inhibited radiographic progression of RA versus placebo at week 26.
“These results show a significant impact on both signs and symptoms and radiographic progression compared to placebo, as well as improvements in important measures such as ACR response and low disease activity compared to adalimumab,” said Michael Severino, MD, executive vice president of research and development and chief scientific officer of AbbVie in a statement. “We are excited by these strong results which add to the body of evidence that support the potential of upadacitinib to be an important treatment option for patients with [RA].”
The safety profile of upadacitinib was consistent with previously reported results, and no new safety signals were detected. Through week 26, serious adverse events (AEs) occurred in 3.7% of patients receiving upadacitinib, 4.3% of patients receiving adalimumab, and 2.9% of patients on placebo. No deaths were reported in the upadacitinib group, but 2 deaths were reported in both the adalimumab group and the placebo group though week 26.
The positive data from this phase 3 trial continue to support AbbVie’s goal of finding a new foothold in the RA space after it loses its patent exclusivity for Humira, allowing biosimilars of the drug to enter the market. The reference adalimumab grossed $18 billion in sales last year, and one analyst believes that, should upadacitinib receive FDA approval, it could net around $6.5 billion in sales each year.
Despite positive results in this trial, a prior phase 3 study in the same clinical program, SELECT-MONOTHERAPY, raised questions about safety; 1 patient taking the study drug died of a hemorrhagic stroke, caused by a ruptured aneurysm. In the study, serious AEs occurred in 5% and 3% of patients receiving 15-mg and 30-mg doses of the drug, respectively.
Additional results of the SELECT trials will be presented at a future medical meeting, said AbbVie. According to a recent statement, the drug maker plans global regulatory submissions for upadacitinib for RA later this year.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.